Medication cascades where new drugs are prescribed to treat the side effects of existing treatments are a significant yet under-recognized contributor to polypharmacy and adverse drug events among older adults with multimorbidity. This review examines current evidence on the epidemiology, risk factors, pathophysiology, clinical features, and optimal strategies for prevention and management of medication cascades in this population. Emphasis is placed on guideline-based interventions, multidisciplinary approaches, and recent advances in deprescribing practices, aiming to inform clinicians on practical, mechanism-oriented approaches to minimize iatrogenic harm and optimize therapeutic outcomes.
The management of older adults with multimorbidity often necessitates complex pharmacotherapy. While polypharmacy is sometimes clinically appropriate, it increases the risk of medication cascades sequential prescribing where one drug’s adverse effect is misinterpreted as a new medical condition, triggering further prescriptions. These cascades can perpetuate unnecessary medication use, leading to adverse drug reactions (ADRs), increased healthcare utilization, and diminished quality of life. Recognizing, preventing, and managing medication cascades is vital in geriatric medicine, particularly as the prevalence of chronic disease and multimorbidity rises globally.
Medication cascades are common in older adults, with studies reporting prevalence rates of 10–25% among those with polypharmacy. The risk escalates with increasing age, number of comorbidities, and medication count. Notable cascades include prescribing loop diuretics for calcium channel blocker-induced edema, anticholinergic agents for antipsychotic-induced extrapyramidal symptoms, and proton pump inhibitors for NSAID-induced dyspepsia. The clinical and economic burden is substantial, with medication cascades contributing to preventable hospitalizations, falls, cognitive impairment, and increased healthcare costs.
The pathophysiology underlying medication cascades is multifactorial. Age-related pharmacokinetic and pharmacodynamic changes such as decreased renal and hepatic clearance, altered receptor sensitivity, and polypharmacy-induced interactions heighten susceptibility to ADRs. Furthermore, complex comorbidity profiles can mask or mimic drug side effects, making accurate attribution challenging. Cognitive impairment and sensory deficits further complicate medication review, increasing the risk of cascade initiation and perpetuation.
Key risk factors for medication cascades include advanced age, multiple chronic conditions (e.g., diabetes, heart failure, COPD), cognitive impairment, high medication burden, fragmented care, lack of medication reconciliation, and transitions between care settings. Healthcare system factors, such as limited access to geriatric expertise and insufficient communication among providers, also play a pivotal role. Inadequate patient education and low health literacy may further impede recognition of ADRs, contributing to unnecessary prescriptions.
Medication cascades may present with non-specific symptoms such as dizziness, falls, confusion, urinary incontinence, or gastrointestinal disturbances. These symptoms are frequently misattributed to aging or underlying disease progression rather than ADRs. Clinicians should maintain a high index of suspicion for medication-induced symptomatology, particularly following recent medication changes or escalation in regimen complexity.
Diagnosing medication cascades requires thorough medication history-taking, ongoing review of new symptoms, and careful temporal correlation between drug initiation and clinical changes. Tools such as the Medication Appropriateness Index (MAI), Beers Criteria, and STOPP/START criteria aid in identifying potentially inappropriate medications and drug-induced harms. Multidisciplinary team assessments, including input from pharmacists and geriatricians, are invaluable for differentiating disease progression from medication-related effects.
Prevention and management of medication cascades center on deprescribing and optimizing pharmacotherapy. Key strategies include routine medication reconciliation, utilizing clinical decision support tools, and conducting regular comprehensive geriatric assessments. Shared decision-making with patients and caregivers is essential, ensuring that therapeutic goals align with patient preferences and life expectancy. When a cascade is identified, review for opportunities to taper or discontinue unnecessary medications, substitute with safer alternatives, or employ non-pharmacological interventions.
Recent advances have focused on the implementation of deprescribing algorithms, electronic health record (EHR)-integrated alerts for high-risk medication combinations, and structured pharmacist-led interventions. Clinical trials such as the D-PRESCRIBE and SENATOR studies have demonstrated reductions in inappropriate prescribing and medication-related hospitalizations through structured deprescribing interventions. Artificial intelligence-driven predictive tools are emerging to identify patients at highest risk for cascades, enabling targeted prevention strategies.
Current guidelines from the American Geriatrics Society, National Institute for Health and Care Excellence (NICE), and Choosing Wisely advocate for regular medication review in older adults, with explicit consideration of medication cascades. Recommendations emphasize the avoidance of prescribing to treat ADRs without first considering deprescribing the causative agent, the involvement of multidisciplinary teams, and the use of validated screening tools to identify inappropriate polypharmacy.
Medication cascades contribute to significant morbidity and healthcare utilization in older adults with multimorbidity. Proactive prevention, early detection, and a structured approach to deprescribing are essential to minimize iatrogenic harm. Integrating guideline-based strategies, multidisciplinary care, and leveraging technological advances can optimize pharmacotherapy and improve outcomes in this vulnerable population. Ongoing research and education are needed to empower clinicians and health systems to recognize and address medication cascades as a critical aspect of geriatric care.
1.
High Rate of Surgical Success in Complex NSCLC With Neoadjuvant Chemoimmunotherapy
2.
Papillary thyroid cancer: New markers offer hope for tailored treatment
3.
What Comes After Cancer?
4.
FDA Expands Durvalumab Label to Operable Lung Cancer
5.
In postmenopausal women with hormone receptor-positive tumors, obesity increases the risk of breast cancer recurrence.
1.
Finding Support: Connecting with the Vitiligo Community
2.
Essential Updates in Hematology in Daily Practice
3.
Neoepitope Vaccines in Oncology: Precision, Sequencing, and Immunotherapy Frontiers
4.
Living Better With Advanced Cancer Through Supportive Care
5.
Understanding Epoetin and Its Role in Treating Chronic Kidney Disease
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases
2.
Updates on Standard V/S High Risk Myeloma Treatment
3.
What Therapy Would Yield the Best Outcomes In Patients with R/R B-cell ALL?
4.
Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases - Part II
5.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part II
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation